Opioid-sparing effects of perioperative paracetamol and nonsteroidal anti-inflammatory drugs (NSAIDs) in children

Ivan Wong1,2, Celia St John-Green2 & Suellen M. Walker1,3

1 Department of Anaesthesia, Great Ormond St Hospital for Children NHS Foundation Trust, London, UK
2 School of Clinical Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
3 Portex Unit: Pain Research, UCL Institute of Child Health, London, UK

Keywords
pain; postoperative; child; analgesics; opioid; analgesics; non-narcotic; anti-inflammatory agents; nonsteroidal

Correspondence
Suellen M. Walker, Portex Unit: Pain Research, UCL Institute of Child Health and Great Ormond St Hospital for Children NHS Foundation Trust, 30 Guilford St, London WC1N 1EH, UK
Email: suellen.walker@ucl.ac.uk

Section Editor: Per-Arne Lonnqvist

Accepted 4 March 2013
doi:10.1111/pan.12163

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

The copyright line for this article was changed on 28th July 2014 after original online publication.

Summary
Background and Objectives: Perioperative pain in children can be effectively managed with systemic opioids, but addition of paracetamol or nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce opioid requirements and potentially improve analgesia and/or reduce adverse effects.

Methods: A systematic literature search was conducted to identify trials evaluating postoperative opioid requirements in children and comparing NSAID and/or paracetamol with placebo. Studies were stratified according to design: continuous availability of intravenous opioid (PCA/NCA) vs intermittent ‘as needed’ bolus; and single vs multiple dose paracetamol/NSAIDs. Primary outcome data were extracted, and the percentage decrease in mean opioid consumption was calculated for statistically significant reductions compared with placebo. Secondary outcomes included differences in pain intensity, adverse effects (sedation, respiratory depression, postoperative nausea and vomiting, pruritus, urinary retention, bleeding), and patient/parent satisfaction.

Results: Thirty-one randomized controlled studies, with 48 active treatment arms compared with placebo, were included. Significant opioid sparing was reported in 38 of 48 active treatment arms, across 21 of the 31 studies. Benefit was most consistently reported when multiple doses of study drug were administered, and 24 h PCA or NCA opioid requirements were assessed. The proportion of positive studies was less with paracetamol, but was influenced by dose and route of administration. Despite availability of opioid for titration, a reduction in pain intensity by NSAIDs and/or paracetamol was reported in 16 of 29 studies. Evidence for clinically significant reductions in opioid-related adverse effects was less robust.

Conclusion: This systematic review supports addition of NSAIDs and/or paracetamol to systemic opioid for perioperative pain management in children.

Introduction
Systemic opioids are utilized for management of perioperative pain in children of all ages (1,2). As there are significant developmental changes in both the pharmacokinetic and pharmacodynamic profile of opioids, doses need to be adjusted according to age and weight and titrated against individual response to optimize analgesia and minimize adverse effects (3,4). This can be achieved by a range of systemic opioid delivery methods, including continuous background infusion, scheduled intermittent boluses (5), nurse-controlled analgesia (NCA) (2), or patient-controlled analgesia (PCA) (1).

Multi-modal analgesia is recommended for the management of pediatric perioperative pain (3,6,7) and has the potential to improve analgesic efficacy by simultaneously targeting different analgesic mechanisms and/or reducing the dose requirements of single agents, thereby minimizing dose-dependent adverse effects. Addition of nonsteroidal anti-inflammatory drugs (NSAIDs) and/or
paracetamol (acetaminophen) to postoperative opioid regimes is well supported by analyses of adult data (8–11). The quantity and quality of evidence related to pediatric perioperative pain management continue to increase (3,12), and a recent meta-analysis reported a decrease in opioid dose requirements by perioperative NSAID administration in children (13).

Variations in design methodology and assessment tools can influence the sensitivity of pediatric analgesic clinical trials (14). This qualitative systematic review aims to stratify evidence according to study design and sensitivity and use within study comparisons to assess the degree to which addition of NSAIDs and/or paracetamol alters postoperative systemic opioid requirements in children. In addition, changes in secondary outcomes (pain scores, drug-related adverse effects, and patient or parental satisfaction) will be summarized.

Methods

Search strategy

Relevant studies were identified by searching electronic databases (PubMed, Embase, CINAHL, Cochrane Library, NHS Evidence) for randomized controlled trials (RCTs) evaluating combinations of systemic paracetamol and/or NSAIDs with systemic opioids for postoperative pain management in children. Key words were used to identify the ‘population’ (Children, Pediatric, Pediatric, Neonate, Child, Newborn), ‘intervention’ (paracetamol OR acetaminophen OR NSAIDs OR individual drug names AND opioid OR individual opioid names), and ‘outcomes’ (opioid sparing, morbidity, pain score, sedation, respiratory depression, PONV, pruritus, urinary retention, and patient/parent satisfaction). Titles and abstracts up to January 2012 were included in the search. Additional relevant titles were identified by manual search of original articles, reviews, and related correspondence. Data were identified, extracted, and presented in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (www.prisma-statement.org).

Selection criteria

The full reports of RCTs were retrieved and evaluated. Two authors (I.W. and C.S.J.G.) independently assessed whether studies met the inclusion criteria, and all three authors discussed and resolved any discrepancies. Criteria for inclusion included the following:

1. Study type: double blind, placebo-controlled trials quantifying the effect of paracetamol and/or NSAID vs placebo on systemic opioid requirements;
2. Participants: children (0–18 years) undergoing surgery under general anesthesia;
3. Interventions: multiple or single doses of study drug (paracetamol or NSAID) were administered perioperatively (defined as the first dose administered within an hour prior to induction or following wound closure) by any systemic route (oral, rectal, intramuscular, or intravenous).

Studies were excluded if they had no control group, ongoing regional analgesia, or nonstandardized use of other analgesics that could confound the opioid dose requirements.

Data extraction

Details of the study protocol were extracted and tabulated, including: age range of patients; number of patients in each treatment arm; type(s) and duration of surgery; dose regimes for study drugs and opioid (dose, frequency, timing, route and method of delivery); method of pain assessment; criteria for opioid administration; adverse effects; and duration of follow-up. Each included study was graded for quality and scored using the Jadad criteria (15). In addition, the retrieved reports were grouped according to the following aspects of study design:

1. Continuous availability of intravenous opioid titrated according to individual response by PCA, NCA, or variable rate continuous infusion;
2. Intermittent as needed opioid bolus administration;
3. Use of regular repeated doses of paracetamol/NSAIDs for at least 24 h;
4. Use of single dose or less than 6 h paracetamol/NSAIDs.

Secondary outcome data were extracted and included measures of (i) potential opioid-related adverse effects (sedation, respiratory depression, postoperative, nausea and vomiting, pruritus, and urinary retention); (ii) NSAID (increased bleeding, renal dysfunction) and paracetamol (overdose/toxicity) adverse effects; (iii) pain scores; and (iv) patient and/or parent satisfaction.

Analysis

The primary outcome was opioid dose requirement in the postoperative period. Studies are reported as ‘positive’ if a statistically significant reduction in opioid requirements was documented in pair-wise comparisons between the treatment (i.e., paracetamol and/or NSAID) and placebo arm, as previously used in an analysis of similar adult trials (16). The difference between
the means of the treatment arms was expressed as a percentage of the corresponding value in the placebo group (\(\frac{\text{placebo} - \text{treatment/placebo}}{\text{placebo}}\times 100\)). Treatment groups in which opioid consumption was not statistically significantly different from the placebo group were designated as ‘negative’ and assigned an opioid-sparing effect of zero. Due to variability in methodology and reporting, within study comparisons of secondary outcomes in treatment (NSAID or paracetamol) vs placebo groups are reported as being increased, decreased, or not different.

Results

Description and stratification of retrieved studies

The systematic literature search yielded 104 relevant titles of which 31 met the inclusion criteria (Figure 1). All included studies were placebo-controlled blinded trials with quality scores of 3–5 on the Jadad scale (15). Recruited children ranged in age from 1.5 months to 17 years old, and all received systemically administered opioids for perioperative analgesia. Several studies included multiple active treatment arms, but only those allowing comparison of opioid consumption in an active and placebo group were included. In total, 988 children were allocated to placebo control arms, and 1636 children received study drugs (paracetamol and/or NSAIDs). Numbers within treatment groups ranged from 13 to 84 subjects. Based on design methodology, studies were stratified according to the availability of opioid (continuous titration vs intermittent bolus) and the duration of study drug administration (either repeat dose for ≥24 h, or single dose ≤6 h) into four groups (Group A–D; Figure 1).

In 10 of 31 studies, intravenous opioid was continuously available for titration (Group A and B; Table 1). Morphine (17–24) or fentanyl (25,26) was administered via nurse-controlled (NCA; \(n = 2\)) or patient-controlled (PCA; \(n = 8\)) bolus administration.
| Author (reference no.) | Surgery and duration (mean ± sd of control group unless stated) | Intervention drug, route, and age (mean ± sd unless stated) | Timing, frequency, and dose of study drug administration | Control and age (mean ± sd unless stated) | Opioid | Timing, frequency, and dose of opioid | Reported opioid dose-sparing effect (%) reduction |
|------------------------|---------------------------------------------------------------|---------------------------------------------------------------|----------------------------------------------------------|------------------------------------------|--------|----------------------------------------|-----------------------------------------------|
| GROUP A: Titration of systemic opioid (PCA or NCA) and study drug for ≥ 24 h |
| Hong et al. (26) | Ureteroneocystostomy Range: 65–135 mins | Paracetamol IV (n = 31) Range: 6–24 months | LOADING: 15 mg kg⁻¹ at end of surgery | Saline (n = 32) Range: 6–22 months | Fentanyl IV-NCA or parent controlled analgesia with background | LOADING DOSE: 0.5 mcg kg⁻¹ at end of surgery | POSITIVE* (54%) |
| | | | BOLUS (in NCA pump): 1.5 mg kg⁻¹ with 30 min lockout | | | | BACKGROUND: 0.25 mcg kg⁻¹ h⁻¹ for 72 h | Control – 18.1 ± 4.6 mcg kg⁻¹ day⁻¹, total dose in first 24 h post-op, mean ± sd |
| | | | INFUSION: 1.5 mg kg⁻¹ h⁻¹ for 72 h | | | BOLUS: 0.25 mcg kg⁻¹ with 30 min lockout | POSITIVE* (57%) |
| | | | 6 h maximum: 15 mg kg⁻¹ paracetamol | | | TRIGGER: CHEOPS > 4 (4–13) | Paracetamol – 20 |
| | | | | | | | Control – 43 mcg kg⁻¹, cumulative fentanyl dose first 3 days, mean ± sd |
| Rugyte et al. (18) | Thoracic pectus correction Range: 90–225 mins | Ketoprofen IV (n = 14) Range: 13–15 years | LOADING: 1 mg kg⁻¹ at end of surgery | Saline (n = 17) Range: 10–15 years | Morphine IV-PCA with background | LOADING DOSE: 40 mcg kg⁻¹ | POSITIVE* (27%) |
| | | | MAINTENANCE: 1 mg kg⁻¹ at 8 h and 16 h | | | BOLUS: 20 mcg kg⁻¹ with 5 min lockout | Ketoprofen – 490 ± 240 |
| | | | | | | BACKGROUND: 5 mcg kg⁻¹ h⁻¹ | Control – 670 ± 200 mcg kg⁻¹ total dose in first 24 h post-op, mean ± sd |
| | | | | | | TRIGGER: patient dependent | POSITIVE* (57%) |
| | | | | | | | Paracetamol – 20 |
| | | | | | | | Control – 43 mcg kg⁻¹, cumulative fentanyl dose first 3 days, mean ± sd |
| Van der Mareel et al. (17) | Major abdominal or thoracic (noncardiac) surgery Range: 60–365 mins | Paracetamol PR (n = 29) Range: 0–9 months | LOADING: 30–40 mg kg⁻¹ at induction | Placebo (n = 25) Range: 0–10 months | Morphine IV-PCA with background | LOADING DOSE: 100 mcg kg⁻¹ at end of surgery | NEGATIVE* (10) |
| | | | MAINTENANCE: 20 mg kg⁻¹6–8 hrlly for 48 h | | | BACKGROUND: 5–30 mcg kg⁻¹ h⁻¹ (depending on gestational age and bolus requirement) | Placeparacetamol – 7.91 |
| | | | | | | BOLUS: 5 mcg kg⁻¹ with 10 min lockout | (6.59–14.02) |
| | | | | | | TRIGGER: VAS ≥ 4 (0–10) | Control – 7.19 |
| | | | | | | | (5.45–12.06) mcg kg⁻¹ h⁻¹, total dose in first 48 h post-op, median (25–75th percentile) |
| Author | Surgery and duration (mean ± s of control group unless stated) | Intervention drug, route, and age (mean ± s unless stated) | Timing, frequency, and dose of study drug administration | Control and age (mean ± s unless stated) | Opioid | Timing, frequency, and dose of opioid | Reported opioid dose-sparing effect (% reduction) |
|--------|---------------------------------------------------------------|-----------------------------------------------------------|--------------------------------------------------------|----------------------------------------|--------|--------------------------------------|-----------------------------------------------|
| Munro et al. (19) | Posterior spinal fusion 331 ± 62 mins | Ketorolac IV (n = 20) 13.9 ± 1.3 years | LOADING: 0.5 mg kg⁻¹ at end of surgery MAINTENANCE: 0.5 mg kg⁻¹ every 6 h for 36 h | Saline (n = 19) 14.1 ± 1.2 years | Morphine IV-PCA with background | LOADING DOSE: 50–100 mcg kg⁻¹ BOLUS: 20 mcg kg⁻¹ (lockout not stated) BACKGROUND: 10 mcg kg⁻¹ h⁻¹ TRIGGER: patient | EQUIVOCAL POSITIVE* (33%) Ketorolac – 0.06 ± 0.3 Control – 0.09 ± 0.06 mcg kg⁻¹ day⁻¹ during PACU, mean ± s POSITIVE* (30%) Ketorolac – 0.7 ± 0.4 Control – 1 ± 0.5 mcg kg⁻¹ day⁻¹ post-op day 2, mean ± s NEGATIVE (11% n.s.) Ketorolac – 0.8 ± 0.3 Control – 0.9 ± 0.4 mcg kg⁻¹ day⁻¹ on post-op day 1 POSITIVE* (Diclofenac 43%, Combination 36%) Diclofenac – 435 (101–1054) Combination – 484 (126–1214) Control – 759 (688–1914) NEGATIVE (Paracetamol 17% n.s) Paracetamol – 627 (124–1339) mcg kg⁻¹, total dose in first 24 h post-op, median (range) |
| Marton et al. (20) | Open Appendicectomy Duration not reported | Paracetamol PR (n = 20) Range: 5–12 years Diclofenac PR (n = 20) Range: 6–13 years Combination (n = 20) Range: 7–13 years | LOADING: paracetamol 20 mg kg⁻¹ AND/OR diclofenac 1 mg kg⁻¹ MAINTENANCE: paracetamol 15 mg kg⁻¹ 6 hly AND/OR diclofenac 1 mg kg⁻¹ 8 hly for 24 h post-op | Control: no treatment (n = 20) Range: 5–13 years | Morphine IV-PCA with background | BOLUS: 20 mcg kg⁻¹ with 5 min lockout BACKGROUND: 4 mcg kg⁻¹ h⁻¹ infusion for first 12 h post-op TRIGGER: patient | POSITIVE* (Diclofenac 43%, Combination 36%) Diclofenac – 435 (101–1054) Combination – 484 (126–1214) Control – 759 (688–1914) NEGATIVE (Paracetamol 17% n.s) Paracetamol – 627 (124–1339) mcg kg⁻¹, total dose in first 24 h post-op, median (range) |
| Sutters et al. (22) | Orthopedic surgery 178.2 ± 105.8 mins | Ketorolac IV (n = 36) 12.6 ± 3.5 years | LOADING: 1 mg kg⁻¹ in recovery MAINTENANCE: 0.5 mg kg⁻¹ 6 hly for 48 h post-op | Saline (n = 32) 12.6 ± 4.2 years | Morphine IV-PCA | LOADING DOSE: NCA boluses in recovery BOLUS: 16 mcg kg⁻¹ with 10 min lockout TRIGGER: patient | POSITIVE* (47%) Ketorolac – 3.37 ± 2.66 Control – 6.38 ± 4.36 mg, total dose in first 24 h post-op, mean ± s |
| Author         | Surgery and duration | Intervention drug, route, and age                  | Timing, frequency, and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid                  | Timing, frequency, and dose of opioid | Reported opioid dose-sparing effect (% reduction) |
|---------------|----------------------|--------------------------------------------------|----------------------------------------------------------|------------------------------------------|-------------------------|--------------------------------------|------------------------------------------------|
| Sims et al. (21) | Emergency open appendicectomy 39 ± 12 mins | Indomethacin PR (n = 13) 10.1 ± 1.8 years          | LOADING: 2 mg·kg⁻¹ at end of surgery                     | Placebo (n = 15) 10.7 ± 2.1 years       | Morphine IV-PCA          | BOLUS: 20 mg·kg⁻¹ with 3 min lockout TRIGGER: patient | POSITIVE* (44%) Indomethacin – 0.51 ± 0.34 Placebo – 0.91 ± 0.46 mg, total dose first 36 h post-op, mean ± SD |
| Antila et al. (25) | Tonsillectomy 17 ± 7 mins | Ketoprofen IV (n = 15) 12.5 ± 2.3 years           | 2 mg·kg⁻¹ at induction PLUS 2 mg·kg⁻¹ infusion over 6 h post-op | Saline (n = 15) 12.5 ± 1.9 years       | Fentanyl IV-PCA          | BOLUS: 0.5 mg·kg⁻¹ with 5 min lockout TRIGGER: patient | POSITIVE* (14%) Ketoprofen – 11.9 ± 8.8 Placebo – 13.9 ± 7.9 mg·kg⁻¹ total dose in first 24 h post-op, mean ± SD |
| Oztekin et al. (24) | Tonsillectomy ± adenoidectomy 57.8 ± 3.33 mins | Diclofenac PR (n = 20) 8.40 ± 0.53 years          | 1 mg·kg⁻¹ prior to incision                              | Control: no treatment (n = 20) 8.90 ± 0.46 years | Morphine IV-PCA with background | LOADING DOSE: 50 mg·kg⁻¹ at end of surgery BOLUS: 20 mg·kg⁻¹ bolus with 5 min lockout BACKGROUND: 4 mg·kg⁻¹ h⁻¹ infusion TRIGGER: patient | POSITIVE* (24%) Diclofenac – 130 ± 11.3 Control – 170 ± 9.22 microgram·kg⁻¹, in PACU, mean ± SD |
| Vetter et al. (23) | Orthopedic surgery (osteotomy, arthrodesis, ORIF) 113 ± 42 mins | Ketorolac IV (n = 25) 13 ± 2.0 years              | 0.8 mg·kg⁻¹ at end of surgery                            | Control: no treatment (n = 25) 13 ± 2.0 years | Morphine IV-PCA          | LOADING DOSE: 0.05 to 0.3 mg·kg⁻¹ in recovery BOLUS: 15 mg·kg⁻¹ with 10 min lockout TRIGGER: patient | POSITIVE* (81%) Ketorolac – 0.017 ± 0.008 Control – 0.026 ± 0.011 mg·kg⁻¹ h⁻¹, in first 12 h post-op, mean ± SD |

*Positive, statistically significant opioid dose-sparing effect reported by authors; Negative, no statistically significant difference in opioid requirements.

PR, per rectum; IV, intravenous; IM, intramuscular.
Lockout periods ranged from 10 to 30 min for NCA and 3 to 10 min for PCA, and a background infusion was included in six studies (four PCA and both NCA studies). In the 21 studies in Group C (27–30) and Group D (31–46) (Table 2), opioid was available on an ‘as needed’ or ‘PRN’ basis, with nurse administration triggered by a predetermined pain score using either a formal assessment tool (16 studies) or global nursing assessment and patient request (five studies) (Table 3).

Across the 31 studies, thirty-eight different drug groups were compared with placebo (Figure 1). Paracetamol and an NSAID were directly compared within four studies, with three also evaluating the combination of paracetamol and NSAID. Additional within study comparisons included dose-dependent effects of paracetamol (37,39) or ketoprofen (41); different routes of administration of ketoprofen (36,38,47); or administration of ketorolac at the beginning or end of surgery (42). This increased the number of groups in which opioid consumption was measured to 48 treatment arms and 31 placebo controls (one per study) (Table 4).

**Opioid consumption**

Significant decreases in opioid consumption by NSAID and/or paracetamol were reported in 21 of the 31 studies, four did not demonstrate any dose-sparing effects, and in six studies, both positive and negative results were reported for different treatment arms (Table 1 and 2). Overall, positive effects were reported in 38 of 48 treatment arms (Figure 2).

In Group A studies (seven studies with nine treatment arms), surgery was of moderate to major severity, and systemic opioid was available for immediate titration by the patient (PCA) or by nursing staff (NCA bolus plus background). In addition, study drug administration and evaluation continued for at least 24 h following surgery. Seven of nine treatment arms were positive. Two studies reported no significant benefit with addition of rectal paracetamol (17,20). Overall, opioid dose requirements were reduced by 31.6% (95% CI: 16.5–46.6) (Table 4). Opioid sparing was reported in all Group B studies, with a mean reduction of 24.3%, but with wide variability, as only three studies were available.

Significant reduction in opioid dose was reported in five of six treatment arms in Group C (mean 24.5% 95% CI 6.3–42.6) and in 23 of the 30 active treatment arms in Group D (mean 24%; 95% CI: 16.4–31.5) (Table 4). Overall, the majority of Group C/D studies demonstrated significant opioid sparing, but with much greater variability in reported results.

**Paracetamol vs NSAID vs combination**

A higher proportion of positive studies were reported in NSAID (27 of 31; 87%) than in paracetamol (7 of 13; 54%) treatment arms. Four studies included direct comparison of an NSAID and paracetamol. Rectal diclofenac (1 mg kg\(^{-1}\) intraoperative and 8 hrly for 24 h) produced opioid sparing, but by comparison, rectal paracetamol was less effective (40 mg kg\(^{-1}\) intraoperative and 30 mg kg\(^{-1}\) 8 hrly) (27) or showed no benefit (20 mg kg\(^{-1}\) loading and 15 mg kg\(^{-1}\) 6 hrly) (20). Ibuprofen 15 mg kg\(^{-1}\) PR was more effective than paracetamol 40 mg kg\(^{-1}\) PR (27 vs 19% reduction) (35), and preoperative oral administration of naproxen 10 mg kg\(^{-1}\) was more effective than paracetamol 20 mg kg\(^{-1}\) (19% vs nonsignificant difference) (33).

Positive opioid sparing by diclofenac (1 mg kg\(^{-1}\) 8 hrly PR) was further enhanced by addition of paracetamol 30 mg kg\(^{-1}\) 8 hrly PR (27), but not by paracetamol 20 mg kg\(^{-1}\) PR loading and 15 mg kg\(^{-1}\) 6 hrly (20). While both paracetamol 40 mg kg\(^{-1}\) PR and ibuprofen 15 mg kg\(^{-1}\) PR reduced opioid requirements following adenoiectomy, combining the two drugs provided no additional benefit (35). A single combined dose of ketorolac and paracetamol markedly reduced postanesthesia care unit (PACU) opioid requirements, but effects of the individual drugs were not assessed (31).

**Within study comparisons: dose response and route of administration**

Three studies included dose-response comparisons. Dose-dependent increases in opioid sparing in PACU were reported following 20, 40, and 60 mg kg\(^{-1}\) rectal paracetamol (27 vs 54 vs 73%, respectively) (39). Conversely, rectal paracetamol doses of 10, 20, or 40 mg kg\(^{-1}\) had no significant effect in PACU following cleft palate repair (37). Intravenous ketoprofen 0.3, 1, and 3 mg kg\(^{-1}\) reduced the proportion of children requiring fentanyl for 2 h following adenoiectomy, with minimal dose-related differences (21, 24, and 35% reduction, respectively) (41).

Administration of the same dose of ketoprofen by different routes demonstrated benefit with intravenous but not oral administration (47), and similar degrees of opioid sparing following intravenous vs rectal (38) or intramuscular administration (36). There have been no direct comparisons of paracetamol by different routes. Intravenous (26) but not rectal (17,20) paracetamol reduced 24-h opioid requirements. Wide variability in individual plasma paracetamol concentrations was noted following rectal administration (0.8–59.9 mg l\(^{-1}\)) (17).
| Author                  | Study characteristics group C and D: interventions, analgesic administration and opioid-sparing effects |
|-------------------------|--------------------------------------------------------------------------------------------------------|
|                        | Surgical intervention, route and age (mean ± SD of control group unless stated)                      |
|                        | Intervention drug, route and age (mean ± SD unless stated)                                           |
|                        | Timing, frequency and dose of study drug administration                                              |
|                        | Control and age (mean ± SD unless stated)                                                            |
|                        | Opioid                                                                                               |
|                        | Frequency and dose of opioid trigger (pain score) for administration                                  |
|                        | Opioid dose-sparing effect (% reduction)                                                              |
| **GROUP C: Intermittent opioid bolus and study drug for ≥ 24 h** |                                                                                                       |
| Mireskandari et al. (27) | Cleft palate repair 81.7 ± 30.1 mins                                                                   |
|                         | Paracetamol PR (n = 30) 2.1 ± 0.8 years                                                              |
|                         | Diclofenac PR (n = 30) 2.2 ± 1.1 years                                                               |
|                         | Combination (n = 30) 2.0 ± 0.5 years                                                                 |
|                         | Placebo PR (n = 30) 2.3 ± 1 year                                                                       |
|                         | Pethidine IM BOLUS: 1 mg kg⁻¹ IM TRIGGER: CHEOPS > 7                                                   |
|                         | POSITIVE* (9 – 47%)                                                                                   |
|                         | Paracetamol – 88.3 ± 8.3 (9%)                                                                         |
|                         | Diclofenac – 70.7 ± 10 (27%)                                                                         |
|                         | Combined – 51 ± 9.5 (47%)                                                                             |
|                         | Control – 97.1 ± 13.9                                                                                |
|                         | Total pethidine dose in first 48 h post-op                                                            |
|                         | Paracetamol – 6.2 ± 0.6 (11%)                                                                         |
|                         | Diclofenac – 4.9 ± 0.7 (28%)                                                                          |
|                         | Combined – 3.6 ± 0.7 (47%)                                                                            |
|                         | Control – 6.8 ± 0.9                                                                                  |
|                         | No. of doses in first 48 h post-op, mean ± SD                                                         |
|                         | Paracetamol – 0.6 ± 0.6 (11%)                                                                         |
|                         | Diclofenac – 0.7 ± 0.2 (28%)                                                                          |
|                         | Combined – 0.7 ± 0.2 (47%)                                                                            |
|                         | Control – 0.9 ± 0.2                                                                                    |
| Kokki et al. (28)       | Tonsillectomy 25 ± 12 mins                                                                            |
|                         | Ketoprofen IV Pre-op (n = 47) 10 ± 1 years post-op (n = 42) 12 ± 3 years                             |
|                         | LOADING: 0.5 mg kg⁻¹ after induction (n = 47) OR end of surgery (n = 42) MAINTENANCE: 3 mg kg⁻¹ infusion |
|                         | Saline (n = 20) 11 ± 1 years                                                                          |
|                         | Oxycodone IV or IM BOLUS: 0.05 mg kg⁻¹ IV or 0.1 mg kg⁻¹ IM TRIGGER: VAS > 30 mm                       |
|                         | NEGATIVE                                                                                             |
|                         | Preop ketoprofen – 4.1 ± 2.7 (19% n.s.) post-op ketoprofen – 3.7 ± 2.4 (27% n.s.) Control – 5.1 ± 2.7 |
|                         | No. of doses in first 24 h post-op, mean ± SD                                                        |
| Maunuksela et al. (29)  | Ophthalmic, general or orthopedic surgery Control group: 50.1 ± 39.4 mins                            |
|                         | Ibuprofen PR (n = 64) 7.7 ± 2.7 years                                                                |
|                         | LOADING: 10 mg kg⁻¹ MAINTENANCE: total 40 mg kg⁻¹ 6–8 hrly for 24 h                                    |
|                         | Placebo z (n = 64) 7.4 ± 2.7 years                                                                    |
|                         | Morphine or Oxycodone (different centers) IV or IM BOLUS: 0.1 mg kg⁻¹ IV in recovery; 0.15 mg kg⁻¹ IM |
|                         | EQUIVOCAL                                                                                             |
|                         | POSITIVE* (orthop surgery 36%)                                                                       |
|                         | Ibuprofen (n = 12) 0.27 ± 0.2                                                                            |
|                         | Control (n = 19) 0.42 ± 0.23                                                                            |
|                         | (other surgery 25% n.s.)                                                                             |
|                         | Ibuprofen (n = 52) 0.09 ± 0.1                                                                            |
|                         | Control (n = 45) 0.12 ± 0.1 mg kg⁻¹, total opioid dose in first 24 h post-op, mean ± SD                |
Table 2 Continued

| Author (reference no.) | Surgery and duration (mean ± SD of control group unless stated) | Intervention drug, route and age (mean ± SD unless stated) | Timing, frequency and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid | Frequency and dose of opioid trigger (pain score) for administration | Opioid dose-sparing effect (%) reduction |
|-------------------------|---------------------------------------------------------------|----------------------------------------------------------|--------------------------------------------------------|------------------------------------------|--------|---------------------------------------------------------------------|---------------------------------------------|
| Maunuksela et al. (30)  | Orthopedic or general surgery 0.85 ± 0.61 h                  | Indomethacin IV (n = 51) 7.0 ± 5.1 years                 | BOLUS: 0.35 mg kg\(^{-1}\) at end of surgery         | Placebo (n = 49) 6.1 ± 4.3 years         | Morphine IV or IM | BOLUS: 0.1 mg kg\(^{-1}\) IV in recovery, 0.15 mg kg\(^{-1}\) IM on ward | POSITIVE* (28%)
Indomethacin - 0.24 ± 0.17 Control - 0.33 ± 0.21 mg kg\(^{-1}\), total morphine dose in first 24 h post-op, mean ± SD |
| GROUP D: Intermittent opioid bolus and Single dose study drug |                                                                 |                                                          | MAINTENANCE: 0.07 mg kg\(^{-1}\) h\(^{-1}\) for 24 h |                                                                 |                                                                 | TRIGGER: Maunuksela score >3 or patient request |
| Hong et al. (31)        | Inguinal hernia repair (day case) 33.0 ± 11.7 mins            | Ketorolac + Paracetamol IV (n = 28) 28.4 ± 15.5 months   | BOLUS: 0.35 mg kg\(^{-1}\) at end of surgery     | Control: no treatment (n = 27) 28.0 ± 13.3 months | Fentanyl IV | BOLUS: 0.5 mcg kg\(^{-1}\) TRIGGER: Wong-Baker score >2 | POSITIVE* (61%)
Ketorolac-Paracetamol – 0.54 ± 0.3 Control – 1.37 ± 0.2 microgram kg\(^{-1}\), in PACU, mean ± SD |
| Dashti et al. (32)      | Adenotonsillectomy Duration not reported                     | Paracetamol PR (n = 53) 10.2 ± 2.84 years               | 1 mg kg\(^{-1}\) ketorolac + 20 mg kg\(^{-1}\) paracetamol after induction |                                                                 |                                                                 | TRIGGER: VAS >40 mm |
| Korpela et al. (33)     | Adenoidectomy (day case) Duration not reported               | Paracetamol oral (n = 30) Median & range: 1.7 (0.8 – 5) years Naproxen oral (n = 30) median & range: 1.9 (0.8 – 7.8) years | 40 mg kg\(^{-1}\) given after induction            | Placebo (n = 30) median and range: 1.7 (0.8 – 6.2) years | Fentanyl IV | BOLUS: 10 mcg kg\(^{-1}\) TRIGGER: OPS >4 | EQUIVOCAL
POSITIVE* (Naproxen 19%)
Naproxen – 17/30 (19%)
Paracetamol – 20/30 (5% n.s.) Control – 21/30 Proportion requiring fentanyl in first 2 h postop Note: data only from groups given standardized intraoperative analgesia (pethidine 1 mg kg\(^{-1}\)) |
| Sheeran et al. (34)     | Adenotonsillectomy (day case) Duration not reported          | Rofecoxib oral (n = 23) 7.2 ± 1.8 years                 | 1 mg kg given 0.5 h before induction                | Placebo (n = 22) 7.6 ± 2.2 years         | Morphine IV | BOLUS: 25 mcg kg\(^{-1}\) TRIGGER: nurse assessment | NEGATIVE (0%)
Rofecoxib – 39 ± 28 Control – 39 ± 32 microgram kg\(^{-1}\), in first 24 h post-op, mean ± SD |
Table 2 Continued

| Author (reference no.) | Surgery and duration (mean ± SD of control group unless stated) | Intervention drug, route and age (mean ± SD unless stated) | Timing, frequency and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid | Frequency and dose of opioid trigger (pain score) for administration | Opioid dose-sparing effect (%) reduction |
|------------------------|---------------------------------------------------------------|-----------------------------------------------------------|----------------------------------------------------------|----------------------------------------|--------|--------------------------------------------------------------------|----------------------------------------|
| Viitanen et al. (35)   | Adenoidectomy (day case) 30 ± 9 mins                         | Paracetamol PR (n = 40), 1.0–6.4 years                    | 40 mg·kg⁻¹ paracetamol; 15 mg·kg⁻¹ ibuprofen; combination given at induction | Placebo (n = 40) Range: 1.0–6.3 years | Pethidine (meperidine) IV | BOLUS: 5 or 10 mg TRIGGER: OPS >3 | POSITIVE* (Paracetamol 19%, Ibuprofen 27%, Combination 28%) |
| Tuomilehto et al. (36) | Adenoidectomy Duration not reported                         | Ketoprofen IV (n = 40) Median: 30 (15–75) months        | 2 mg·kg⁻¹ IV at induction OR 2 mg·kg⁻¹ IM at induction | Saline (n = 40) Median: 33 (16–85) months | Fentanyl IV TRIGGER: Maunuksela >3 | BOLUS: 0.5 mcg·kg⁻¹ TRIGGER: CHIPPS >4 | POSITIVE* (IV 28% IM 23%) |
| Bremerich et al. (37)  | Cleft palate repair Control group 109.9 ± 29.1 mins          | Paracetamol PR mg·kg⁻¹ (n = 20) 11.7 ± 8.8 months 20 mg·kg⁻¹ (n = 20) 12.1 ± 10.4 months 40 mg·kg⁻¹ (n = 20) 9.5 ± 9.0 months | 10 mg·kg⁻¹ (n = 20), 20 mg·kg⁻¹ (n = 20), or 40 mg·kg⁻¹ (n = 20), given at induction | Placebo (n = 20) 12.5 ± 11.7 months | Piritramide IV TRIGGER: CHIPPS >4 | BOLUS: 25 mcg·kg⁻¹ TRIGGER: CHIPPS >4 | NEGATIVE |

© 2013 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd

Pediatric Anesthesia 23 (2013) 475–495

484

Perioperative opioid sparing by NSAID/paracetamol in children

I. Wong et al.
| Author                  | Procedure          | Surgery and duration (mean ± SD of control group unless stated) | Intervention drug, route and age (mean ± SD unless stated) | Timing, frequency and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid dose-sparing effect (% reduction) |
|------------------------|--------------------|----------------------------------------------------------------|------------------------------------------------------------|--------------------------------------------------------|----------------------------------------|-----------------------------------------|
| Kokki et al. (38)      | Adenoidectomy      | Duration not reported                                           | Ketoprofen PR \(n = 42\) Median 33 (17–90) months Ketoprofen IV \(n = 42\) Median: 44 (15–97) months | 25 mg PR 30 mins prior to induction Or 25 mg IV at induction | Placebo PR & saline IV \(n = 39\) Median: 45 (14–73) months | Fentanyl IV BOLUS: 0.5 mcg kg\(^{-1}\) in recovery TRIGGER: Maunuksela >3 | POSITIVE* (PR 24% IV 22%) PR – 27/42 IV – 28/42 Control - 33/39 Proportion requiring rescue analgesia in PACU POSITIVE* (PR 52% IV 63%) PR – 9/42 IV – 7/42 Control – 17/39 Proportion requiring ≥ 3 rescue doses in PACU EQUIVOCAL NEGATIVE IV – 30/40 Oral – 28/40 Control – 15/20 Proportion requiring rescue analgesia in PACU POSITIVE* Oral – 6/40 IV – 3/40 Control – 6/20 Proportion requiring ≥ 3 rescue doses in PACU POSITIVE* (28%) Ketoprofen – 21/30 Control – 26/29 Proportion requiring fentanyl in first 2 h POSITIVE* (29%) Ketoprofen – 44 Control – 62 Total doses fentanyl per group first 2 h post-op |
| Tuomilehto et al. (47) | Adenoidectomy      | Duration: 17 (8–37) mins                                       | Ketoprofen PO \(n = 40\) Median: 50 (20–101) months Ketoprofen IV \(n = 40\) Median: 32 (16–82) months | 1 mg kg\(^{-1}\) PO 30 mins prior to induction Or 1 mg kg\(^{-1}\) IV at induction | Saline PO & IV \(n = 20\) Median: 46 (15–101) months | Fentanyl IV BOLUS: 0.5 mcg kg\(^{-1}\) in recovery TRIGGER: Maunuksela >3 | |
| Kokki et al. (40)      | Strabismus surgery | Median (quartiles): 30 (23–45) mins                           | Ketoprofen IV \(n = 30\) Median (quartiles): 83 (50–112) months | LOADING: 1 mg kg\(^{-1}\) after induction MAINTENANCE: 1 mg kg\(^{-1}\) infusion over 2 h | Saline \(n = 29\) Median (quartiles): 64 (46–94) months | Fentanyl IV BOLUS: 1.0 mcg kg\(^{-1}\) TRIGGER: Maunuksela >3 | POSITIVE* (28%) Ketoprofen – 21/30 Control – 26/29 Proportion requiring fentanyl in first 2 h POSITIVE* (29%) Ketoprofen – 44 Control – 62 Total doses fentanyl per group first 2 h post-op |
Table 2 Continued

| Author (reference no.) | Surgery and duration (mean ± SD of control group unless stated) | Intervention drug, route and age (mean ± SD unless stated) | Timing, frequency and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid | Frequency and dose of opioid trigger (pain score) | Opioid dose-sparing effect (% reduction) |
|------------------------|---------------------------------------------------------------|----------------------------------------------------------|------------------------------------------------------|------------------------------------------|--------|------------------------------------------------|----------------------------------------|
| Korpela et al. (39)    | Inguinal surgery, adenoidectomy, general surgery (day case) | Paracetamol PR (n = 90), 20 mg kg⁻¹ range: 1.0–7.2 years | BOLUS: 0.1 mg kg⁻¹ (n = 30), 1.1–7.7 years morphine IV | 0% | POSITIVE* (20 mg 27%, 40 mg 54%, 60 mg 73%) | false |
|                        | Duration not reported                                         | 40 mg kg⁻¹ range: 1.0–7.2 years                          | BOLUS: 0.3 mg kg⁻¹ (n = 55), 1.0 mg kg⁻¹ (n = 55), 3.0 mg kg⁻¹ (n = 55) | Placebo (n = 30), 1.1–7.7 years | Paracetamol BOLUS: 20 mg kg⁻¹ – 0.8 | true |
|                        |                                                                | 60 mg kg⁻¹ range: 1.1–7.8 years                          | given at induction | Fentanyl V (median 10th–90th percentile): 41 (15–79) months | Paracetamol 40 mg kg⁻¹ – 0.5 | true |
|                        |                                                                |                                                        |                                                      |                                                        | Paracetamol 60 mg kg⁻¹ – 0.3 | Control – 1.1 |
|                        |                                                                |                                                        |                                                      |                                                        | Total no. of doses of morphine per patient in first 2 h post-op 1.0 mg 21%, 1.0 mg 24%, 3.0 mg 35% | true |
|                        |                                                                |                                                        |                                                      |                                                        | Ketoprofen 0.3 mg kg⁻¹ – 65% | true |
|                        |                                                                |                                                        |                                                      |                                                        | Ketoprofen 1.0 mg kg⁻¹ – 62% | true |
|                        |                                                                |                                                        |                                                      |                                                        | Ketoprofen 3.0 mg kg⁻¹ – 53% | true |
|                        |                                                                |                                                        |                                                      |                                                        | Control – 82% Proportion requiring fentanyl in first 2 h post-op EQUITOCAL (Pre-op 9%, post-op 0%) | true |
|                        |                                                                |                                                        |                                                      |                                                        | Pre-op Ketorolac – 2/55 | true |
|                        |                                                                |                                                        |                                                      |                                                        | post-op Ketorolac – 9/55 | true |
|                        |                                                                |                                                        |                                                      |                                                        | Control – 7/55 Proportion requiring fentanyl in first 1.5 h post-op POSITIVE* (13%) | true |
|                        |                                                                |                                                        |                                                      |                                                        | Ketoprofen – 5/80 – 64% | true |
|                        |                                                                |                                                        |                                                      |                                                        | Control – 65/84 – 77% Proportion requiring fentanyl in PACU | true |

© 2013 The Authors. Pediatric Anesthesia published by John Wiley & Sons Ltd. Pediatric Anesthesia 23 (2013) 459–465
| Author                     | Surgery and duration                              | Intervention drug, route and age (mean ± SD unless stated) | Timing, frequency and dose of study drug administration | Control and age (mean ± SD unless stated) | Opioid                  | Frequency and dose of opioid trigger (pain score) for administration | Opioid dose-sparing effect (% reduction) |
|----------------------------|----------------------------------------------------|------------------------------------------------------------|----------------------------------------------------------|------------------------------------------|-------------------------|-----------------------------------------------------------------------|------------------------------------------|
| Bean-Lijewski et al. (44)  | Ilioinguinal or general surgery (day case)         | Ketorolac IV (n = 29) 4.0 ± 2.2 years                      | 0.75 mg kg⁻¹ at induction                                | Saline (n = 28) 4.2 ± 3.0 years          | Pethidine               | BOLUS: 0.5 mg kg⁻¹ TRIGGER: nurse assessment or patient request        | POSITIVE* (46%)                        |
|                            | Duration: 93.0 ± 21.2 mins                         |                                                            |                                                          |                                          |                         |                                                                       |                                           |
| Sutters et al. (45)        | Tonsillectomy (day case)                           | Ketorolac IM (n = 45) 7.1 ± 2.4 years                     | 1.0 mg kg⁻¹ at end of surgery                            | Saline (n = 42) 7.1 ± 2.2 years         | Fentanyl IV             | BOLUS: 0.5 mcg kg⁻¹ TRIGGER: nurse assessment in recovery              | POSITIVE* (26%)                        |
|                            | Duration not reported                              |                                                            |                                                          |                                          |                         |                                                                       |                                           |
| Watcha et al. (46)         | Adenotonsillectomy, moderate orthopedic or plastic surgery | Ketorolac IV (n = 32) 8.3 ± 3.8 years                    | 0.9 mg kg⁻¹ at induction                                | Saline (n = 32) 10.0 ± 3.6 years        | Morphine V              | BOLUS: 50 mcg kg⁻¹ in PACU TRIGGER: VAS > 60 mm or OPS > 6             | POSITIVE* (43%)                        |
|                            | Duration: 87 ± 50 mins                             |                                                            |                                                          |                                          |                         |                                                                       |                                           |

*Positive, statistically significant opioid dose-sparing effect reported by authors; Negative, no statistically significant difference in opioid requirements.

PR, per rectum; IV, intravenous; IM, intramuscular.
| Author (reference no.) | Age       | Pain scale (range) | Pain score | Sedation | Respiratory depression | PONV | Pruritis | Urinary retention | Bleeding |
|-------------------------|-----------|--------------------|------------|----------|------------------------|------|----------|------------------|----------|
| Group A                 |           |                    |            |          |                        |      |          |                  |          |
| Hong et al. (26)        | 0.5–2 years | CHEOPS 4–13        | –          | –        | 0                      | –    | –        | X                | X        |
| Rugyte et al. (118)     | 10–15 years | VAS 0–10           | –          | =        | =                      | =    | =        | =                | +        |
| Van der Marel et al. (17)| 0–10 months | VAS 0–10           | –          | =        | X                      | X    | X        | X                | X        |
| Munro et al. (19)       | 11–17 years | Numerical 0–10     | –          | =        |                        | =    | =        | =                | =        |
| Morton et al. (20)      | 5–13 years | Numerical 0–3      | –          | =        |                        | =    | =        | =                | =        |
| Sutters et al. (22)     | Mean 12.6 ± 4 years | Wong-Baker Faces 0–5 | –          | X        | X                      | =    | =        | =                | 0        |
| Sims et al. (21)        | ≥ 7 years (mean 10 years) | VAS 0–10 | –          | =        | X                      | X    | =        | =                | X        |
| Group B                 |           |                    |            |          |                        |      |          |                  |          |
| Antila et al. (25)      | 9–15 years | VAS 0–10           | –          | =        | X                      | =    | X        | =                | X        |
| Oztekin et al. (24)     | 5–14 years | Numerical 0–10     | –          | =        | 0                      | =    | X        | =                | =        |
| Vetter et al. (23)      | 8–16 years | VAS 0–10           | –          | =        | X                      | =    | =        | =                | =        |
| Group C                 |           |                    |            |          |                        |      |          |                  |          |
| Mireskandari (27)       | 1.5–5 years | CHEOPS              | –          | =        | combined vs placebo    | =    | =        | =                | X        |
| Kokki et al. (28)       | 3–16 years | VAS 0–100          | –          | =        | X                      | =    | X        | =                | =        |
| Maunuksela et al. (29)  | 4–12 years | OPS 0–9            | –          | =        | Observer – Patient      | =    | =        | =                | =        |
| Maunuksela et al. (30)  | 1–16 years | Numerical 0–3      | –          | =        | X                      | =    | X        | =                | X        |
| Group D                 |           |                    |            |          |                        |      |          |                  |          |
| Hong et al. (31)        | 1–5 years | Wong-Baker Faces 0–5 | –          | =        | X                      | =    | =        | =                | X        |
| Dasthi et al. (32)      | 7–15 years | VAS 1–100          | –          | =        | X                      | =    | X        | =                | X        |
| Korpela et al. (33)     | 1–7 years | OPS 0–9            | –          | =        | X                      | =    | X        | =                | X        |
| Sheeran et al. (34)     | >3 years  | CHEOPS 4–13        | –          | =        | X                      | =    | X        | =                | X        |
| Vistanen et al. (35)    | 1–6 years | OPS 0–9            | –          | =        | X                      | =    | X        | =                | X        |
| Tuomilehto et al. (36)  | 1–9 years | Modified Maunuksela scale 0–10 | –        | =        | X                      | =    | =        | =                | =        |
| Bremerich et al. (37)   | 1–24 months | CHIPPS 0–10 | –          | =        | X                      | 0    | X        | =                | X        |
| Kokki et al. (38)       | 1–9 years | Maunuksela 0–10    | –          | =        | X                      | =    | X        | =                | =        |
| Tuomilehto et al. (47)  | 1–9      | Maunuksela 0–10    | –          | =        | X                      | =    | X        | =                | =        |
| Kokki et al. (40)       | 1–12 years | Maunuksela 0–10    | –          | =        | X                      | =    | X        | =                | X        |
| Korpela et al. (39)     | 1–11 years | Observer NRS 0–100 | –          | =        | X                      | =    | X        | =                | X        |
| Kokki et al. (41)       | 1–7 years | Maunuksela 0–10    | –          | =        | 0                      | =    | X        | =                | =        |
| Romsing et al. (42)     | 5–15 years | Poker Chip Tool 0–4 | –          | =        | X                      | X    | =        | =                | =        |
| Nikanne et al. (43)     | 1–7 years | Maunuksela 0–10    | –          | =        | X                      | =    | X        | =                | =        |
| Bean-Lijewski et al. (44)| 1–11 years | CHEOPS 4–13      | –          | =        | X                      | =    | X        | =                | =        |
| Sutters et al. (45)     | 7.1 ± 2.4 years | Oucher 0–5 | –          | =        | X                      | X    | X        | =                | =        |
| Watcha et al. (46)      | 5–15 years | VAS 0–100 Oucher 0–9 | –          | X        | X                      | =    | X        | =                | X        |

Pain score: ‘−’ no significant difference in control and intervention groups, ‘+’ higher pain score in intervention group compared with control, ‘−’ lower pain scores in intervention group compared with control, and ‘X’ not reported.

Opioid-related adverse effects: ‘−’ equal incidence in both control and intervention groups, ‘+’ higher incidence in intervention group compared with control, ‘−’ lower incidence in intervention group compared with control, ‘0’ indicate absence of this complication in both groups and ‘X’ not reported.

CHEOPS, Children’s Hospital of Eastern Ontario Pain Scale; VAS, Visual Analog Scale; OPS, Observer Pain Score; CHIPPS, Children’s and Infants Postoperative Pain Scale; NRS, numerical rating scale.
Pain assessment and pain scores

All studies incorporated pain assessment, but by a range of different tools. Self-report included numerical rating (0–30 or 0–10), visual analog scales (0–10 or 0–100) or faces scales. Observer tools ranged from an overall numerical rating to composite measures of specific behavioral and physiological responses (e.g., Children’s Hospital of Eastern Ontario Pain Scale (CHEOPS) and COMFORT scales) (Table 3).

In Group A and B studies, intravenous bolus opioid was triggered by the patient (PCA), who titrated themselves to similar pain scores in two of eight studies (20,21). Six studies reported improved pain scores with addition of NSAID/paracetamol. Outcomes included different composite measures of pain (i.e., area under the pain intensity–time graph for the first 24 h (18), a main effect of treatment with repeated measures ANOVA to 36 h (22), overall pain score for first 12 h (23)). Others reported significant reductions in pain score only at some time points (i.e., the first 48 h (19), the initial six postoperative hours (25) or the first hour in PACU (24)).

In NCA studies, a background infusion plus opioid bolus administration by a nurse or trained parent following urologic surgery (26), or by a nurse or investigator in intensive care after major abdominal or thoracic surgery (17), resulted in effective titration to similar pain scores. In the latter study, a high proportion of patients were mechanically ventilated, and both Observer VAS and COMFORT scores were low in paracetamol and placebo groups (17).

In Group C and D studies, opioid was available on an ‘as needed’ or ‘PRN’ basis. Nurse administration was triggered by a predetermined pain score using a formal assessment tool (16 studies) or global nursing assessment and patient request (five studies). Pain scores in treatment groups were reported to be significantly lower in the active treatment arm in 10 studies; reduced in some subgroups or on some subscales in 3; equivalent in 6; and were not reported in two studies (Table 3).

Opioid-related adverse effects

Postoperative nausea and vomiting (PONV) was compared in 27 of 31 studies, with six study arms in five studies reporting a significant reduction in the paracetamol and/or NSAID group (Table 3). The degree of
opioid sparing tended to be greater (47%, 95% CI 22–72) in treatment groups with less PONV when compared to studies with equivalent PONV (26%, 95% CI 20–31). Within study comparisons found a significant reduction in the incidence of PONV with 40 and 60 mg⋅kg\(^{-1}\) PR, but not 20 mg⋅kg\(^{-1}\) which also had less effect on opioid requirement (39). Preoperative, but not postoperative, ketorolac reduced both opioid requirement and the number of children vomiting following tonsillectomy (42).

Ten studies noted no difference in significant adverse respiratory effects, reported as either a lack of respiratory depression or no difference in respiratory rate or episodes of desaturation. Sedation was assessed in 17 of 31 studies: 14 reported no difference, and three studies with positive opioid sparing also reported less sedation in the active treatment group. The incidence of oversedation (defined as Ramsay sedation score >4 on 8-point scale) was reduced when paracetamol (26) or ketorolac plus paracetamol (31) was used with fentanyl NCA; and ‘somnolence’ and IV fentanyl bolus use in PACU was less frequent with addition of ketoprofen (43).

No difference in adverse urinary effects (i.e., need for catheterization or difficulty voiding) was noted in nine studies, but fewer children required a urinary catheter following orthopedic surgery if they received IV ketorolac (1 of 25 vs 7 of 25 in the control group) (23). Six studies recorded pruritus, but there were no differences between treatment and control groups.

**NSAID/paracetamol adverse effects**

No cases of accidental overdose or toxicity related to paracetamol were reported.

Alteration in bleeding was the main potential NSAID adverse effect evaluated, particularly as many studies were conducted in children undergoing tonsillectomy. The incidence or degree of perioperative bleeding was reported in 21 NSAID studies: seven each of ketoprofen or ketorolac, two of diclofenac or ibuprofen, and single studies of naproxen or rofecoxib. Bleeding following paracetamol was assessed in three studies, of which two included an NSAID treatment arm. Methods for reporting this outcome varied and included the following: direct measurements of intraoperative blood loss or postoperative blood loss in drains; graded but subjective assessments of intraoperative blood loss by the surgeon; rate of re-operation/interventions to control increased bleeding; or statements that no patients had significant bleeding. Following tonsillectomy and/or adenoidectomy, measured perioperative blood loss was not increased following ketorolac 1 mg⋅kg\(^{-1}\) (42) or ketoprofen (25,28). Graded assessment of blood loss by the surgeon found no increase in intraoperative bleeding with ketorolac (45), ibuprofen (35), or ketoprofen (25,36,38,41). Although not quantified, no cases of increased bleeding were reported following rofecoxib (34), naproxen (33), or paracetamol (32,33). In one study, the rate of ‘more than normal’ bleeding was greater following ketoprofen (12 of 80 vs 3 of 84; \(P = 0.037\)), but no patients required re-operation (43).

Cases of bleeding requiring re-operation were reported in both placebo and/or NSAID groups. Two patients were excluded from analysis following ketorolac as they required an immediate return to the operating theater to control surgical bleeding (42); one patient was withdrawn due to bleeding at 5 h following ketoprofen (18); two patients required diathermy under local anesthesia at 4 or 26 h following ketoprofen (28); and one patient required nasopharyngeal packing overnight following diclofenac (24). Bleeding requiring surgical intervention was also reported in three patients given placebo (24,25,46).

Measured blood loss did not differ from control groups during spinal fusion with ketorolac (19) or ophthalmic, general or orthopedic surgery with ibuprofen (29). No significant episodes of bleeding were reported with diclofenac for cleft palate repair (27), or with ketorolac for orthopedic (23) or day case general surgery (44), despite a greater increase in measured bleeding time (53.4 ± 74.8 s) in the latter study.

**Patient/parent satisfaction**

Relatively few studies evaluated overall satisfaction with treatment, and none included patient satisfaction as an outcome. Higher levels of parental satisfaction in the active treatment arm either during the in-hospital stay (26,31) or during both the time in hospital and following discharge (34) were reported. No comparison was made with patient satisfaction, but these studies enrolled infants (26,31) or young children (>3 years; mean 7 years) (34).

**Discussion**

Recommendations to use multimodal analgesic therapy for perioperative pain management in children (3,7) are supported by this qualitative systematic review. Across 31 studies, 38 of 48 active treatment arms reported a statistically significant reduction in opioid requirements with co-administration of NSAID and/or paracetamol in pair-wise comparisons with a placebo group. However, potential publication bias against negative studies cannot be excluded. Evidence for a clinical advantage in terms of improved pain scores or a reduction in adverse effects evaluated, particularly as many studies were conducted in children undergoing tonsillectomy.
effects was less robust. However, variability in study design, method of opioid delivery, duration of study drug administration, and reported outcome measures had an impact on the likelihood and degree of positive findings.

Opioid dose requirements

Opioid-sparing effects with perioperative NSAIDs and paracetamol have been well documented in meta-analyses of adult studies (10,11,48), using a standardized measure of opioid dose (24 h total PCA morphine consumption) (10)[additional details in (8)]. In the current pediatric series, all studies that evaluated cumulative PCA morphine dose (mcg kg$^{-1}$ day$^{-1}$ in children aged at least 5 years) reported significant reductions in opioid requirements in the first 24 h by regular doses of NSAID (18–22,25)) and in the early postoperative period by a single dose of diclofenac (24) or ketorolac (23). These studies were also included in a meta-analysis of 28 pediatric studies, which calculated the standardized mean difference in opioid requirements for individual trials, and reported significant opioid sparing in PACU and during the first 24 h by NSAID (13). We have also evaluated studies of perioperative paracetamol and found more variable results: rectal paracetamol did not reduce PCA (20) or NCA (17) opioid requirements, but IV paracetamol reduced NCA opioid requirements in children aged 6–24 months (26).

Variable methodology in pediatric analgesic studies influences the sensitivity for detecting differences and the ability to combine data across studies (14,49). MchL et and colleagues (13) also noted significant heterogeneity, but benefit with NSAID was maintained in subgroup analyses of the effects of surgery (adenotonsillectomy vs orthopedic or general surgery) and timing of administration (intra- vs postoperative NSAID) (13). In the current studies, the degree of opioid sparing tended to be higher and more consistent when opioid was readily available for titration (i.e., PCA or NCA) and repeated doses of study drug were given (i.e., Group A design). Studies with opioid available on an intermittent ‘PRN’ basis and evaluating the effect of a single dose of NSAID/paracetamol (i.e., Group D design) also reported significant opioid sparing, but there was much greater variability in the degree of difference and in the outcome being evaluated. Many were conducted following surgery with relatively low analgesic requirements, and group data such as the proportion of patients requiring opioid in PACU, rather than individual dose requirements, were the primary outcomes. Some statistically significant differences may have limited clinical significance (e.g., mean differences of less than one dose per patient). In addition, the duration of follow-up was often limited to time in the PACU or the first 1–2 postoperative hours, with only one study reporting a reduction in analgesic requirements following discharge (39). Reduction in PACU opioid requirements with NSAID has also been confirmed by meta-analysis (13) and while reducing early postoperative pain is clearly important, the greater clinical challenge may be to determine whether this translates into reduced analgesic requirements or improved analgesia following discharge. Recent studies confirm that many children experience significant levels of pain at home (50,51), and provision of adequate analgesia following discharge remains an unmet need.

Analgesic efficacy

Recruiting children across wide age ranges necessitates use of different measurement tools, and standardized use of validated measures has been advocated (52) to improve comparison across studies. The observer and self-report pain assessment tools used in the reviewed studies have variable numbers of choices and different linear/ratio characteristics, making it difficult to compare absolute changes in pain ‘score’ or intensity or to evaluate an overall change over time. Pain intensity is often not evaluated in adult analyses as it is assumed that patients will titrate themselves to similar levels of analgesia (10,11); but one analysis found pain intensity was reduced at 24 h by multidose NSAID, but not single-dose NSAID or paracetamol (48). In the pediatric meta-analysis, addition of NSAIDs to opioids reduced pain intensity in the PACU but not the first 24 h (13). In 6 of the 8 PCA studies reviewed here, pain scores were lower in the active treatment arms, despite these older children being able to ‘self-titrate’ their analgesia. It is possible children may tolerate higher levels of pain to avoid opioid-related PONV, as has been suggested in adult studies (12). Intermittent opioid administration by a nurse can have less flexible dosing schedules, additional time constraints, and is reliant on the frequency and sensitivity of pain assessment. Nine of 12 Group D studies reported lower pain scores, suggesting that intermittent dosing in the early postoperative period was less effective for titrating analgesia in the placebo groups.

Analgesic trials in children can pose ethical challenges, particularly in the use of placebo control groups (53). Using a rescue-analgesic design with analgesic sparing as a surrogate efficacy endpoint incorporates the scientific and regulatory advantages of placebo-controlled trials, while ensuring children have analgesia available for immediate titration (53). All studies included in this analysis had opioid available for
Intraoperative analgesia was limited to nitrous oxide anesthetic infiltration. In some early Group C/D studies, received standardized intraoperative opioid and/or local NSAID/paracetamol and placebo treatment arms also intermittent bolus. In the majority of studies, both titration postoperatively, either by PCA/NCA or by intermittent bolus. In the majority of studies, both NSAID/paracetamol and placebo treatment arms also received standardized intraoperative opioid and/or local anesthetic infiltration. In some early Group C/D studies, intraoperative analgesia was limited to nitrous oxide alone (29,30,39,44-46). Opioid was available for titration in PACU, and all studies reported significantly higher analgesic requirements in the placebo group (29,30,39,44-46). Differences in intraoperative analgesia may also contribute to a cross-study variability in opioid sparing, particularly when assessment is limited to the first few postoperative hours.

### Opioid-related adverse effects

Although statistically significant reductions in opioid requirements demonstrate analgesic benefit, clinical benefit is enhanced if there is also a reduction in opioid-related adverse effects. Individual studies are rarely powered for these secondary outcomes and definitions or thresholds for reporting adverse effects vary across studies. Postoperative vomiting is an important cause of morbidity, a leading concern for parents and patients, and may require readmission (54,55). In the first 24 postoperative hours, NSAIDs had a similar impact on PONV in meta-analyses of adult (odds ratio 0.7, 95% CI 0.53–0.88) (10) and pediatric (odds ratio 0.75, 95% CI 0.57–0.99) (13) studies. In addition to patient (i.e., age, gender) and anesthetic factors, the type of surgery can have a significant effect. Many pediatric studies have been conducted following tonsillectomy, which has a high rate of PONV, and NSAIDs had a greater impact in this subgroup (13). There have been insufficient studies to specifically evaluate PONV in other high-risk surgical groups, such as strabismus, although beneficial effects of NSAID on both opioid sparing and vomiting have been reported (40). Although some studies evaluated the number of episodes of vomiting in individual children (28,40), the majority of studies reported the incidence of vomiting within treatment arms, and it was not possible to differentiate effects on the frequency or severity of vomiting. Other opioid-related adverse effects, such as urinary retention and pruritus are less common, are less likely to be reported in individual studies, and no significant differences were reported in a meta-analysis (13).

Respiratory depression is the most feared adverse effect of opioids, with an incidence in large pediatric audits (>10 000 patients) of 0.13% with opioid via continuous infusion, PCA, or NCA (1) and 0.4% with opioid NCA in a younger population (2). Clinical trials are not powered to evaluate this rare outcome and often exclude patients shown to be at highest risk (i.e., neonates, particularly those born preterm, and patients with comorbid conditions such as cardiorespiratory disease and neurodevelopmental impairment) (1,2). Increased sedation, which can be a more reliable indicator of impending respiratory depression, was noted in some placebo groups, but was not sufficient to be associated with respiratory depression or oxygen desaturation (26,31,43).

### Type of surgery

Studies included here and in previous analyses of perioperative opioid dose requirements in children (7,13) include patients undergoing a range of different surgeries, with variable perioperative analgesic requirements. When opioid requirements were relatively high and administration via NCA or PCA was required, results were less variable and the ability to detect significant differences with co-administration of NSAIDs was enhanced. NSAIDs may have specific efficacy against bone pain, and one within study comparison showed benefit with ibuprofen following orthopedic but not general surgery (29). Tonsillectomy not only has an impact on potential opioid-related adverse effects such as PONV, but analgesic benefits must also be weighed against the potential for NSAID-induced bleeding. Cases of post-tonsillectomy bleeding were noted in both NSAID and placebo groups but the number requiring intervention was small. Meta-analyses of pediatric studies have concluded that the risk of bleeding requiring reoperation is not increased by diclofenac for acute pain (56) or NSAIDs following tonsillectomy (57).

### Comparison of study drugs

There is currently insufficient data to determine the relative efficacy of paracetamol or different NSAIDs, and the dose equivalence of different preparations at different ages is not well-established. Overall, the proportion of positive studies was lower with paracetamol, and adult analyses also suggest a greater degree of opioid sparing with NSAIDs vs paracetamol (10). However, pediatric studies may also be confounded by inadequate paracetamol dosing and variability in absorption, particularly when given by the rectal route (17). Within study comparisons found dose-dependent increases in opioid sparing with higher rectal paracetamol dose (37,39). The time to peak plasma concentration varies with the rectal preparation, but can exceed 2 h (58,59). In addition, the equilibration half-life (t½) for the analgesic effect compartment is over 50 min, which further delays time to maximum analgesia (60).
As a result, an adequate effect site concentration may not be achieved following administration of single doses for relatively brief surgical procedures with evaluation in PACU; a design commonly utilized in the studies classified here as Group D, which show wide variability in reported opioid sparing and the greatest number of negative paracetamol studies. Intravenous paracetamol was beneficial in 2 included studies (26,31) and has recently been reported to reduce opioid requirements in neonates and infants following major surgery (61). Recent pharmacokinetic analyses provide further data regarding appropriate dose schedules for intravenous paracetamol (62,63).

Combining an NSAID and paracetamol produced variable benefit in individual studies. Using time-effect profiles at different doses, a recent simulation with paracetamol and ibuprofen suggests analgesic benefit with this combination is more likely to be seen with modest doses of drug and at time points beyond PACU (i.e., >2 h) (64). High doses of NSAID approach a maximum or ceiling effect, and little additional benefit may be gained by adding paracetamol (64). Additive analgesia with paracetamol and NSAID has been demonstrated in adults with acute pain (9,16,65), and although co-administration did not significantly alter opioid requirements, meta-analysis of pediatric studies reported a further reduction in pain intensity during the first 24 h when regular paracetamol was added to NSAID (13).

Limitations and future directions

The current systematic review is limited to a qualitative analysis; however, findings are consistent with a recent meta-analysis which evaluated the impact of NSAID on postoperative opioid requirements in children (13). This meta-analysis provides more detailed quantification of the degree (i.e., standardized mean difference) in opioid requirement, and by combining data for secondary outcomes, such as PONV, can better evaluate effects for which individual studies are inadequately powered. However, significant heterogeneity is often seen in pediatric analgesic studies, with variability in design, study population, and outcome measures. Qualitative reviews can provide further information about which clinical populations are most likely to benefit from the intervention and highlight areas requiring further research. There is an ongoing need for more uniform use of validated pain scores and outcome measures (52) to facilitate comparison and combination of data from different trials. Standardized definitions and reporting of adverse effects or clinical endpoints such as PONV, pruritus, and sedation would also enhance evaluation of relative risks and benefits. Further quantification of clinically significant benefits is likely to require much larger or multi-center studies that are sufficiently powered to detect differences in adverse effects rather than just differences in opioid consumption (10) and/or that have more prolonged follow-up that includes evaluation of pain and function following discharge after short-stay or day case surgery.

Conclusion

NSAIDs and/or paracetamol reduce perioperative opioid requirements in children, and positive effects are most consistently seen when opioid requirements are relatively high and titrated by NCA or PCA. The degree of clinically significant benefit in terms of improved analgesic benefit or reduction in opioid-related adverse effects varies across studies, and there is currently insufficient data to compare the relative efficacy of different drugs. The doses of NSAIDs and/or paracetamol utilized in these trials were not associated with any additional adverse effects. These data provide further support for use of multimodal analgesia for perioperative pain in children.

Acknowledgments

This work was supported in part by funding from a Royal College of Anaesthetists/British Journal of Anaesthesia project grant (SMW).

Conflict of interest

No conflicts of interest declared.

References

1 Morton NS, Errera A. APA national audit of pediatric opioid infusions. *Pediatr Anesth* 2010; 20: 119–125.
2 Howard RF, Lloyd-Thomas A, Thomas M et al. Nurse-controlled analgesia (NCA) following major surgery in 10 000 patients in a children’s hospital. *Pediatr Anesth* 2010; 20: 126–134.
3 Howard RF, Carter B, Curry J et al. Good practice in postoperative and procedural pain. A guideline from the association of paediatric anaesthetists of Great Britain and Ireland. *Pediatr Anesth* 2012; 22: 1–79.
4 Taylor J, Liley A, Anderson BJ. The relationship between age and morphine infusion rate in children. *Pediatr Anesth* 2013; 23: 40–44.
Perioperative opioid sparing by NSAID/paracetamol in children

I. Wong et al.

5 Bouwmeester NJ, Hop WC, van Dijk M et al. Postoperative pain in the neonate: age-related differences in morphine requirements and metabolism. Intensive Care Med 2003; 29: 2009–2015.

6 Lonnqvist PA, Morton NS. Postoperative analgesia in infants and children. Br J Anaesth 2005; 95: 59–68.

7 Duedahl TH, Hansen EH. A qualitative systematic review of morphine treatment in children with postoperative pain. Pediatr Anesth 2007; 17: 756–774.

8 McDaid C, Maund E, Rice S et al. Paracetamol and selective and non-selective non-steroidal anti-inflammatory drugs (NSAIDs) for the reduction of morphine-related side effects after major surgery: a systematic review. Health Technol Assess 2010; 14: 1–153, iii–iv.

9 Ong CK, Seymour RA, Link P et al. Combining paracetamol (acetaminophen) with nonsteroidal antiinflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010; 110: 1170–1179.

10 Maund E, McDaid C, Rice S et al. Paracetamol and selective and non-selective nonsteroidal anti-inflammatory drugs for the reduction in morphine-related side-effects after major surgery: a systematic review. Br J Anaesth 2011; 106: 292–297.

11 Remy C, Marret E, Bonnet F. Effects of acetaminophen on morphine side-effects and consumption after major surgery: meta-analysis of randomized controlled trials. Br J Anaesth 2005; 94: 505–513.

12 Macintyre PE, Schug SA, Scott DA et al. APM/SE Working Group of the Australian and New Zealand College of Anaesthetists and Faculty of Pain Medicine. Acute Pain Management: Scientific Evidence, 3rd edn. Melbourne: ANZCA & FPM, 2010.

13 Michelet D, Andreus-Gallien J, Benalal S et al. A meta-analysis of the use of nonsteroidal antiinflammatory drugs for pediatric postoperative pain. Anesth Analg 2012; 114: 393–406.

14 Hamunen K, Kontinen V. Systematic review on analgesics given for pain following tonsillectomy in children. Pain 2005; 117: 40–50.

15 Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1–12.

16 Hyllested M, Jones S, Pedersen JL et al. Comparative effect of paracetamol, NSAIDs or their combination in postoperative pain management: a qualitative review. Br J Anaesth 2002; 88: 199–214.

17 van der Marel CD, Peters JW, Bouwmeester NJ et al. Rectal acetaminophen does not reduce morphine consumption after major surgery in young infants. Br J Anaesth 2007; 98: 372–379.

18 Rugzeit D, Kokki H. Intravenous ketoprofen as an adjunct to patient-controlled analgesia morphine in adolescents with thoracic surgery: a placebo controlled double-blinded study. Eur J Pain 2007; 11: 694–699.

19 Munro HM, Walton SR, Malviya S et al. Low-dose ketorolac improves analgesia and reduces morphine requirements following posterior spinal fusion in adolescents. Can J Anaesth 2002; 49: 461–466.

20 Morton NS, O’Brien K. Analgesic efficacy of paracetamol and diclofenac in children receiving PCA morphine. Br J Anaesth 1999; 82: 715–717.

21 Sims C, Johnson CM, Bergeso R et al. Rectal indomethacin for analgesia after appendectomy in children. Anaesth Intensive Care 1994; 22: 272–275.

22 Sutters KA, Shaw BA, Gerardi JA et al. Comparison of morphine patient-controlled analgesia with and without ketorolac for postoperative analgesia in pediatric orthopedic surgery. Am J Orthop (Belle Mead NJ) 1999; 28: 351–358.

23 Vetter TR, Heiner EJ. Intravenous ketorolac as an adjuvant to pediatric patient-controlled analgesia with morphine. J Clin Anaesth 1994; 6: 110–113.

24 Öztökin S, Hepaguslar H, Kar AA et al. Preemptive diclofenac reduces morphine use after remifentanil-based anaesthesia for tonsillectomy. Paediatr Anaesth 2002; 12: 694–699.

25 Antila H, Manner T, Kuurila K et al. Ketoprofen and tramadol for analgesia during early recovery after tonsillectomy in children. Pediatr Anaesth 2006; 16: 548–553.

26 Hong JY, Kim WO, Koo BN et al. Fentanyl-sparing effect of acetaminophen as a mixture of fentanyl in intravenous-patient-nurse-controlled analgesia after pediatric urological surgery. Anesthesiology 2010; 113: 672–677.

27 Mireskandari SM, Makarem J. Effect of rectal diclofenac and acetaminophen alone and in combination on postoperative pain after cleft palate repair in children. J Craniofac Surg 2011; 22: 1955–1959.

28 Kokki H, Salonen A. Comparison of pre- and postoperative administration of ketoprofen for analgesia after tonsillectomy in children. Paediatr Anaesth 2002; 12: 162–167.

29 Maunuksela EL, Ryhainen P, Jahnunen L. Efficacy of rectal ibuprofen in controlling postoperative pain in children. Can J Anaesth 1992; 39: 226–230.

30 Maunuksela EL, Ollikola KT, Korpela R. Does prophylactic intravenous infusion of indomethacin improve the management of postoperative pain in children? Can J Anaesth 1998; 35: 123–127.

31 Hong JY, Won Han S, Kim WO et al. Fentanyl-sparing effects of combined ketorolac and acetaminophen for outpatient inguinal hernia repair in children. J Urol 2010; 183: 1551–1555.

32 Dashi G, Amini S, Zanguee E. The prophylactic effect of rectal acetaminophen on postoperative pain and opioid requirements after adenotonsillectomy in children. Middle East J Anaesthesiol 2009; 20: 245–249.

33 Korpela R, Silvola J, Laakso E et al. Oral naproxen but not oral paracetamol reduces the need for rescue analgesic after adenotonsillectomy in children. Acta Anaesthesiol Scand 2007; 51: 726–730.

34 Sheeran PW, Rose JB, Fazi LM, Rofelcoer oxidation administration to paediatric patients undergoing adenotonsillectomy. Pediatr Anesth 2004; 14: 579–583.

35 Vitanen H, Tuovinen N, Vaaraniemi H et al. Analgesic efficacy of rectal acetaminophen and ibuprofen alone or in combination for paediatric day-case adenotonsillectomy. Br J Anaesth 2003; 91: 363–367.

36 Tuomilehto H, Kokki H. Parenteral ketoprofen for pain management after adenotonsillectomy: comparison of intravenous and intramuscular routes of administration. Acta Anaesthesiol Scand 2002; 46: 184–189.

37 Bremerich DH, Neidhart G, Heimann K et al. Prophylactically-administered rectal acetaminophen does not reduce postoperative opioid requirements in infants and small children undergoing elective cleft palate repair. Anesth Analg 2001; 92: 907–912.

38 Kokki H, Tuomilehto H, Tuovinen K. Pain management after adenotonsillectomy with ketoprofen: comparison of rectal and intravenous routes. Br J Anaesth 2000; 85: 836–840.

39 Korpela R, Korvenoja P, Mereotoja OA. Morphine-sparing effect of acetaminophen in pediatric day-case surgery. Anesthesiology 1999; 91: 442–447.

40 Kokki H, Homan E, Tuovinen K et al. Preoperative treatment with i.v. ketoprofen reduces pain and vomiting in children after strabismus surgery. Acta Anaesthesiol Scand 1999; 43: 13–18.

41 Kokki H, Nikanne E, Tuovinen K. I.v. intraoperative ketoprofen in small children during adenoidectomy: a dose-finding study. Br J Anaesth 1998; 81: 870–874.

42 Romsing J, Östergaard D, Walther-Larsen S et al. Analgesic efficacy and safety of preoperative vs postoperative ketorolac in paediatric tonsillectomy. Acta Anaesthesiol Scand 1998; 42: 770–775.

43 Nikanne E, Kokki H, Tuovinen K. I.v. perioperative ketoprofen in small children during adenoidectomy. Br J Anaesth 1997; 78: 24–27.
50 Power NM, Howard RF, Wade AM et al. Pain and behaviour changes in children following surgery. Arch Dis Child 2012; 97: 879–884.

51 Stewart DW, Ragg PG, Sheppard S et al. The severity and duration of postoperative pain and analgesia requirements in children after tonsillectomy, adenotonsillectomy or inguinal hernia repair. Paediatr Anaesth 2012; 22: 136–143.

52 McGrath PJ, Waleco GA, Turk DC et al. Core outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials: PedIMMPACT recommendations. J Pain 2008; 9: 771–783.

53 Berde CB, Waleco GA, Krane EJ et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics 2012; 129: 354–364.

54 Kovac AL. Management of postoperative nausea and vomiting in children. Paediatr Drugs 2007; 9: 47–60.

55 Carr AS, Brennan L, Courtman S et al. Guidelines on the Prevention of Post-operative Vomiting in Children. The Association of Paediatric Anaesthetists of Great Britain and Ireland, 2009.

56 Standing JF, Ooi K, Keady S et al. Prospective observational study of adverse drug reactions to diclofenac in children. Br J Clin Pharmacol 2009; 68: 243–251.

57 Cardwell M, Siviter G, Smith A. Non-steroi- dal anti-inflammatory drugs and perioperative bleeding in paediatric tonsillectomy. Cochrane Database Syst Rev 2005; 18: CD003591.

58 Anderson BJ, van Lingen RA, Hansen TG et al. Acetaminophen development in children: size matters most. Arch Dis Child 2011; 96: 575–580.

59 Anderson BJ, Woolard GA, Holford NH. Pharmacokinetics of rectal paracetamol after major surgery in children. Paediatr Anaesth 1995; 5: 237–242.

60 Anderson BJ, Woolard GA, Holford NH. Acetaminophen analgesia in children: placebo effect and pain resolution after tonsillectomy. Eur J Clin Pharmacol 2001; 57: 559–569.

61 Poolman J, de Wilde SN, van Dijk M et al. Effect of intravenous paracetamol on postoperative morphine requirements in neonates and infants undergoing major noncardiac surgery: a randomized controlled trial. JAMA 2013; 309: 149–154.

62 Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of intravenous paracetamol in neonates: size matters most. Arch Dis Child 2011; 96: 575–580.

63 Prins SA, Van Dijk M, Van Leeuwen P et al. Pharmacokinetics and analgesic effects of intravenous propacetamol vs rectal paracetamol in children after major craniofacial surgery. Pediatr Anesth 2008; 18: 582–592.

64 Hannam J, Anderson BJ. Explaining the acetaminophen–ibuprofen analgesic interaction using a response surface model. Pediatr Anesth 2011; 21: 1234–1240.

65 Moore RA, Derry CJ, Derry S et al. A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. Eur J Pain 2012; 16: 585–591.